November 23, 2010

Zealand Pharma is a Mid Cap company within the health care sector. This is the fourteenth company to be listed on NASDAQ OMX in Europe in 2010.

Zealand Pharma is a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs for the treatment of metabolic diseases such as diabetes and obesity, as well as gastrointestinal diseases. The company's activities are centered on areas in which it is expected that existing treatments not in a sufficient manner covers the market and consequently creates a market potential for better treatments through the application of peptide-based drugs. Read more at: www.zealandpharma.com

Follow the Zealand Pharma share


 
Chariman of the Board Daniël Jan Ellens is signing the IPO poster.

 
CEO David H. Solomon is signing the IPO poster.

 
CEO David H. Solomon is receiving the IPO present from Head of Capital Markets in Copenhagen, Carsten Borring.

 
CEO David H. Solomon, Chairman of the Board Daniël Jan Ellens and CFO Mats Blom celebrating the listing on NASDAQ OMX in Copenhagen.